GSK Jemperli reveals survival profit in uterus most cancers, meets important objective of section 3…
JHVEPhoto GSK (NYSE:GSK) stated its drugs Jemperli (dostarlimab) met the primary objective of progression-free survival (PFS) in sufferers with major superior or recurrent endometrial most cancers in a section 3 trial. Endometrial…